Valuation: Annexon, Inc.

Market Cap 950M 831M 767M 708M 1.34B 90.63B 1.37B 9.16B 3.6B 44.65B 3.57B 3.49B 153B P/E 2026 *
-6.18x
P/E 2027 * -7.4x
Enterprise Value 856M 749M 690M 638M 1.21B 81.62B 1.23B 8.25B 3.24B 40.21B 3.21B 3.14B 138B EV / Sales 2026 *
-
EV / Sales 2027 * 16.3x
Free-Float
93.57%
Yield 2026 *
-
Yield 2027 * -
1 day-2.36%
1 week+6.23%
Current month+1.58%
1 month+23.40%
3 months-0.85%
6 months+10.48%
Current year+15.54%
1 week 5.39
Extreme 5.39
6.51
1 month 4.46
Extreme 4.46
6.51
Current year 4.46
Extreme 4.46
7.18
1 year 2.03
Extreme 2.03
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.81
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 62 09/01/2025
Director/Board Member 65 01/12/2014
Director/Board Member 67 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
06-11Free

Director

65,000 0.0397%
06-11Free

Director

65,000 0.0397%
06-11Fiscal year

Chief Technology Officer

61,292 0.0374%
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%+6.23%+124.81%+54.67% 950M
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.84%+0.37%+59.34%+197.81% 24.25B
Weighted average by Cap. -0.90%-1.42%+51.55%+176.66%

Financials

2026 *2027 *
Net sales - 40.5M 35.42M 32.67M 30.18M 57.26M 3.86B 58.22M 390M 153M 1.9B 152M 149M 6.54B
Net income -188M -165M -152M -140M -266M -17.97B -271M -1.82B -713M -8.85B -707M -692M -30.43B -180M -157M -145M -134M -254M -17.13B -258M -1.73B -680M -8.44B -674M -660M -29.01B
Net Debt -94.47M -82.63M -76.22M -70.4M -134M -9.01B -136M -911M -358M -4.44B -355M -347M -15.26B -292M -255M -236M -218M -413M -27.84B -420M -2.81B -1.11B -13.71B -1.1B -1.07B -47.15B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
10/07/26 $5.800 -2.36% 2,736,861
09/07/26 $5.940 -0.34% 4,836,228
08/07/26 $5.960 -7.31% 7,548,993
07/07/26 $6.430 +7.89% 5,759,444
06/07/26 $5.960 +9.16% 6,778,989
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.800USD
Average target price
13.12USD
Spread / Average Target
+126.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock